



PATENT  
ATTORNEY DOCKET NO. 07180/004003

Certificate of Mailing: Date of Deposit: 8/11/01

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Christine M. Atas Printed name of person mailing correspondence

Christine M. Atas Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: Vassilis I. Zannis et al.

Art Unit: 1645

AUG 23 2001

Serial No.: 09/827,854

Examiner: Not Yet Assigned

Filed: April 5, 2001

Customer No.: 21559

TECH CENTER 1600/290

Title: COMPOUNDS AND METHODS FOR LOWERING CHOLESTEROL  
LEVELS WITHOUT INDUCING HYPERTRIGLYCERIDEMIA

Assistant Commissioner for Patents

Washington, D.C. 20231

REPLY TO NOTICE OF INCOMPLETE REPLY


In reply to the Notice of Incomplete Reply mailed July 13, 2001 (a copy of which is enclosed), Applicant as a small entity submits herewith the following:

Substitute drawings in compliance with 37 CFR 1.84.

If there are any charges, or any credits, please apply them to Deposit Account  
No. 03-2095.

Respectfully submitted,

Date: Aug. 16. 2001


  
Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045  
F:\07180\07180.004003 Reply to Notice of Incomplete Reply.wpd



21559

PATENT TRADEMARK OFFICE



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/827,854	04/05/2001	Vassilis I. Zannis	07180/004003

21559  
 CLARK & ELBING LLP  
 176 FEDERAL STREET  
 BOSTON, MA 02110-2214

RECEIVED

AUG 23 2001

TECH CENTER 1600/2900

CONFIRMATION NO. 6635  
 FORMALITIES LETTER



\*OC000000006295117\*

Date Mailed: 07/13/2001

## NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

*Filing Date Granted*

The U.S. Patent and Trademark Office has received your reply on to the Notice mailed and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

- Substitute drawings in compliance with 37 CFR 1.84 because:

- drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);

*A copy of this notice **MUST** be returned with the reply.*


~\~

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

FIG. 1



2/27

FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D



**FIG. 3A**

**3/27**








FIG. 3B




**FIG. 4A****FIG. 4B**

6/27

**FIG. 5A**



**FIG. 5B**



7/27

FIG. 5C





FIG. 5D



8/27

FIG. 5E





FIG. 5F



9/27

FIG. 6




FIG. 7A

10/27




FIG. 7B






FIG. 7C



11/27

FIG. 8A



12/27

FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A





FIG. 10B



16/27

FIG. 10C





FIG. 10D



17/27

FIG. 11A




FIG. 11B




FIG. 11C






FIG. 11D



18/27

FIG. 12







**FIG. 13A****FIG. 13B****FIG. 13C**

FIG. 14








FIG. 16A

Day 0 4 5 8 0 4 5 8 0 4 5 0 4 5 0 4 5  
Virus: AdGFP AdGFP-E4 AdGFP-E4-185 AdGFP-E4-202  
Dose (pfu):  $2 \times 10^9$   $2 \times 10^9$   $1 \times 10^{10}$   $1 \times 10^{10}$   $2 \times 10^9$   $2 \times 10^9$   
Mouse Strain: E<sup>+/+</sup> C57BL6



23/27

FIG. 16B



24/27

FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18A





FIG. 18B



26/27

FIG. 18C





FIG. 18D



27/27

100 90 80 70 60 50 40 30 20 10 0

